Foghorn Therapeutics Inc.
FHTX
$4.48
-$0.10-2.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -50.49% | -55.33% | 23.02% | -4.88% | 37.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.49% | -55.33% | 23.02% | -4.88% | 37.88% |
| Cost of Revenue | -12.78% | -29.34% | -- | -14.84% | 268.30% |
| Gross Profit | 10.57% | -58.27% | 23.02% | 16.99% | -308.42% |
| SG&A Expenses | -9.53% | -16.09% | -12.81% | -10.77% | -10.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.98% | -8.39% | -17.34% | -13.93% | -13.43% |
| Operating Income | 5.71% | -39.64% | 24.39% | 15.38% | 20.16% |
| Income Before Tax | 11.83% | -40.53% | 19.50% | 16.41% | 23.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.09% | -33.30% | 22.07% | 17.95% | 16.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.09% | -33.30% | 22.07% | 17.95% | 16.55% |
| EBIT | 5.71% | -39.64% | 24.39% | 15.38% | 20.16% |
| EBITDA | 5.54% | -42.56% | 24.80% | 15.71% | 20.72% |
| EPS Basic | 45.66% | 10.52% | 36.81% | 19.14% | 17.40% |
| Normalized Basic EPS | 40.78% | 5.68% | 41.52% | 17.64% | 24.20% |
| EPS Diluted | 45.66% | 10.52% | 36.81% | 19.14% | 17.40% |
| Normalized Diluted EPS | 40.78% | 5.68% | 41.52% | 17.64% | 24.20% |
| Average Basic Shares Outstanding | 48.87% | 48.96% | 23.32% | 1.48% | 1.03% |
| Average Diluted Shares Outstanding | 48.87% | 48.96% | 23.32% | 1.48% | 1.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
